SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Phase IIb clinical study with SOM3355 as a treatment for Huntington’s chorea has been completed.

Barcelona, Spain, March 26th, 2024. SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary Artificial Intelligent (AI) platform, appoints Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

Barcelona, Spain. March 12, 2024. SOM Biotech (“SOM” or the “Company”), a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligent (AI) platform, announces the closure of an internal round for € 5.5 million to secure the completion of the Phase IIb study on Huntington patients with its lead candidate SOM3355.…

SOM Biotech participated in the 10th Drug Discovery Innovation Programme that took place on November 28th -29th- in Barcelona, Spain. Luca Signorile – Computational Chemist of SOM Biotech –performed the presentation on the topic “Re-Discovering Drugs: Advantages, Perspectives, and the role of AI.” During his speech, he gave an insight into the computational side of…

SOM Biotech has participated in the “Clinical Trials Europe 2019” conference, that took place on November 19th -21st- in Barcelona, Spain. The “Clinical Trials Europe 2019”, one of the leading platforms to build partnerships to develop clinical trials, attracts a wide range of innovative research centers and business development teams from biotech and pharma companies.…

SOM Biotech participated in the World Orphan Drug Congress Europe 2019 on November 12th -14th- in Barcelona, Spain, where the company was a Showcase Sponsor. Raul Insa – CEO of SOM Biotech – presented “Case study: Systematic drug re-innovation and clinical evidence in orphan diseases”. SOM Biotech shared its latest findings in drug discovery and…